未知生产厂商
KYN-5356 is an investigational oral small-molecule inhibitor of KAT-II being developed by Kynexis for cognitive impairment associated with schizophrenia (CIAS).
KYN-5356 is an investigational oral small-molecule inhibitor of KAT-II being developed by Kynexis for cognitive impairment associated with schizophrenia (CIAS).
KYN-5356 is an investigational oral small-molecule inhibitor of KAT-II, the primary enzyme responsible for producing kynurenic acid (KYNA) in the brain. Elevated KYNA is associated with disrupted NMDA and alpha-7 nicotinic receptor signaling, contributing to the learning, memory, and executive function deficits characteristic of CIAS.
Cognitive impairment associated with schizophrenia (CIAS)
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
